Enjoy complimentary customisation on priority with our Enterprise License!
The autism spectrum disorder therapeutics market size is forecast to increase by USD 772.65 million, at a CAGR of 7.2% between 2022 and 2027. The market's expansion relies on numerous factors, notably the rising incidence of autism spectrum disorder, the proliferation of public-private partnerships, and the increasing awareness surrounding it. As the prevalence of autism spectrum disorder continues to increase globally, there is a growing demand for related products, services, and interventions to support affected individuals and their families. Additionally, the formation of public-private partnerships facilitates collaboration between government agencies, healthcare providers, and private entities to address the complex needs of individuals with ASD more effectively. Furthermore, heightened awareness campaigns and educational initiatives contribute to greater recognition and understanding of ASD within society, driving the demand for related resources and solutions. Our analysis encompasses these pivotal factors, offering insights into the market dynamics and opportunities for growth.
To learn more about this report, View Report Sample
In the realm of the market, addressing the diverse needs of patients across pediatric patients and adult patient populations is paramount. Behavioral therapies play a central role in managing symptoms, especially considering the communication challenges often associated with ASD. With a focus on understanding the underlying genetic condition, efforts aim to improve the diagnosis rate and reduce the age of diagnosis to ensure timely intervention. Collaboration between hospital pharmacy segment and drug stores facilitates access to essential medications for individuals with autism spectrum disorder.
Further, this market report extensively covers market segmentation by distribution channel (retail pharmacy, hospital pharmacy, and online pharmacy), type (stimulants, selective serotonin reuptake inhibitors, antipsychotic drugs, sleep medications, and others), and geography (North America, Europe, Asia, and Rest of World). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
The market share by the retail pharmacy segment will be significant during the forecast period. There is no cure for ASD, although there are several therapies and drugs available to help manage the symptoms. The market is expected to grow at a rapid pace over the next few years due to the growing awareness and prevalence of the condition and breakthroughs in novel treatment options. Retail pharmacies are the most accessible and convenient source of medications for patients with ASD.
Get a glance at the market contribution of various segments View the PDF Sample
The retail pharmacy segment was valued at USD 841.83 million in 2017. The rising prevalence of autism spectrum disorder has increased the demand for medicines and other treatments. Secondly, the growing awareness about the disorder has resulted in more patients seeking treatment and medication options. Finally, the global expansion of retail pharmacies as well as the availability of online pharmacies has made it easier for people to obtain therapeutic drugs. As more effective treatment choices become available, the demand for drugs and other therapies is expected to increase, and retail pharmacies will play an important role in ensuring that these options are available. Thus, the retail pharmacy segment is expected to drive the growth of the market during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The high prevalence of ASD in the region, rising awareness of the illness, and the availability of advanced treatment options are driving the growth of the market in North America. Because of their widespread presence and the convenience that they offer to patients with ASD, retail pharmacies are the most popular distribution channel in North America. However, due to the availability of modern pharmaceuticals and specialized services, hospital pharmacies and specialty pharmacies are also growing in popularity.
The market is witnessing notable advancements in personalized therapies aimed at addressing the unique needs of patients across all age groups, from pediatric to adult. Pharmaceutical companies are developing innovative therapies to manage symptoms such as aggressive behaviors and mood stabilization associated with ASD. Early diagnosis is crucial, given the challenges in communication and the varying diagnosis rates. With a focus on addressing genetic conditions and disorders like autistic disorder, Asperger's syndrome, and Pervasive Development Disorder (PDD), the market strives to improve the quality of life for individuals with ASD across the globe. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing prevalence of ASD is notably driving the market growth. ASD is a complicated neurodevelopmental illness that affects communication and social interaction abilities as well as the behavior of those diagnosed with it. The disorder is characterized by a variety of symptoms, the severity of which varies from person to person. According to the Center for Disease Control and Prevention (CDC), roughly one in every 54 children in the US has ASD, representing a ten-fold increase in the prevalence of ASD over the past four decades.
Similarly, the World Health Organization (WHO) estimates that one out of every 160 children worldwide has ASD. As the number of individuals who have increased, there is a greater need for suitable therapy alternatives that can assist in controlling the symptoms of the disorder. Further, there is a growing need for drugs and other therapies that can help in managing the symptoms of ASD. Thus, the increasing prevalence is expected to drive the growth of the market during the forecast period.
The increasing interest in personalized medicine is the key trend shaping the market. Personalized medicine procedures for the treatment of ASD are gaining popularity. Personalized medicine is the practice of personalized medical treatments to individual patients based on their genetic, environmental, and lifestyle characteristics. The aim is to provide a more accurate and effective treatment with fewer adverse effects. ASD is a complex condition with diverse symptoms and severity among people. Because of this heterogeneity, developing effective medications that work for all individuals is difficult. Personalized medicine approaches ASD therapy try to solve this issue by providing individualized treatment programs based on the specific needs of each patient.
Furthermore, some studies have discovered that mutations in the SHANK3 gene are linked to a severe form of ASD, and researchers are looking at new treatments that could target this gene. Another area of study is the use of biomarkers to identify specific ASD subtypes and develop tailored treatments. Researchers are looking into a variety of biomarkers such as brain imaging, gene expression, and metabolic indicators to discover ASD subtypes that can respond differently to different treatments. Thus, the increasing interest in personalized medicine for the treatment of ASD is one of the major trends that will drive the growth of the market during the forecast period.
Stringent regulations may impede market growth. Regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play an important role in guaranteeing the safety and efficacy of drugs and other therapies used in the treatment of ASD patients. While antipsychotics have been demonstrated to be beneficial in controlling some of the behavioral symptoms associated with ASD, they are also associated with substantial adverse effects, including weight gain, metabolic abnormalities, and difficulties in mobility.
Additionally, ASD therapies include those that treat the wide variations in both the symptoms as well as the severity of the condition among people with ASD. This diversity in symptoms can make it difficult to create clear regulatory clearance standards and may lead to a lack of clarity among healthcare practitioners about the optimal treatment techniques. Thus, the stringent regulations on ASD therapeutics and treatments will hinder the growth of the market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Bristol Myers Squibb Co. - The company offers autism spectrum disorder therapeutics such as aripiprazole.
The research report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
In the realm of autism spectrum disorder (ASD) therapeutics, addressing the diverse needs of patients across pediatric and adult populations is paramount. Behavioral therapies play a central role in managing symptoms, especially considering the communication challenges often associated with ASD. With a focus on understanding the underlying genetic condition, efforts aim to improve the diagnosis rate and reduce the age of diagnosis to ensure timely intervention. Collaboration between hospital pharmacy segments and drug stores facilitates access to essential medications for individuals with ASD.
Further, in addressing autism spectrum disorder, understanding anxiety and depressive symptoms among individuals, particularly within the children's age group, is paramount. Evaluating symptom severity and exploring underlying mechanisms are crucial for effective drug development and subsequent drug approvals. Consideration of geographic presence and tailored targeted therapies is essential, informed by genetic insights and novel therapies. Remote monitoring offers opportunities for enhanced care, considering factors such as ethnicity and advancements in biotechnology. Collaboration between hospitals and research centers is key in addressing the complexities of neurological disorders and improving social communication outcomes, especially given variations in birth rate.
Market Scope |
|
Report Coverage |
Details |
Page number |
157 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.2% |
Market growth 2023-2027 |
USD 772.65 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
6.12 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd., Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier SAS, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd., PaxMedica Inc., Q BioMed Inc., Scioto Biosciences Inc., Spectrum Pharmaceuticals Inc., Stalicla SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC, and Zynerba Pharmaceuticals Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.